Key result
Second-dose BNT162b2 mRNA vaccination linked to myocarditis in two adolescent brothers.
Why the study?
The mechanisms leading to myocarditis after mRNA vaccination against COVID-19 remain incompletely understood.
Case Report (n=2)
This case report of myocarditis in adolescent siblings following mRNA COVID-19 vaccination suggests a potential need to investigate familial or genetic mechanisms.
Answers are grounded in this paper and cite their sources.
Warrants vigilance for familial myocarditis post-mRNA vaccination; leaves open genetic predisposition for targeted investigation.
The development of myocarditis after receiving messenger RNA vaccination against COVID-19 is well documented, particularly in adolescent and young adult males. We report a case of vaccine-associated myocarditis in adolescent brothers following their second dose of the BNT162b2 mRNA vaccine (Pfizer-BioNTech, Mainz, Germany). This report illustrates the need to better understand the mechanisms leading to myocarditis after mRNA vaccination.
No takes yet. Share an insight, caveat, or question.
Moosmann et al. (2022) conducted a case report in Vaccine-associated myocarditis (n=2). BNT162b2 mRNA vaccine was evaluated. BNT162b2 mRNA vaccination (second dose) was associated with the development of myocarditis in two adolescent brothers, highlighting the need to understand underlying mechanisms.
Synapse has enriched 10 related papers. Consider them for comparative context: